Thanks dino for the info. I did not know about the warrant strike prices.
Did you know, they have warrant strike prices one at 26 and the other one at 62, which will fund them 21 million dollars, they are there for a reason although the years are a little ahead, between I believe 2024-2026.?
Yep, they are going after money/investors. Had to have it.
Yes they are, I’m very excited to be holding this!
This is going to blow the top off very soon. Just think of the pipeline the stage and the FDA fast track designation, market cap where it and where it needs to be. Do not dwell over this at all, this is destined to hit a market cap of 75-100 million, just with those, not to mention a partnership most probably has been or being hammered out, what if a scenario of a buyout, Oh Lord 500 million dollar!!!! Could catapult this stock overnight to 400 dollars minimum buyout price of 500 million dollars, what if big Pharma sees massive potential with this science and the price tag is 2 billion dollars. Hold on to your seats this is going to be massive.
Looks like these guys are onto something. They are going to go down in history for their life saving efforts.
VAL-083 news will be explosive.
I am still here, holding to every and each single share, not going to get shaken out, market makers are dancing around on level 2 as watching the beautiful scenery, there is huge spread at times with this, that in itself shows that this could run, just got to hold, there is not much downside with 10 million market cap biotech with a 2/3 phase in metastatic breast cancer, which got the FDA fast track, I strongly believe they haven't filed for an offering for a reason, very possible they are hammering out the deal with a partnership. 1.5 million float and low OS, only way is up North. This is prepping and being marinated for a huge run, I give it 2 weeks we should be at $20.00, if there are no huge surprises. They could even sell the company for minuscule of 500 million dollars, just think about the stock price at that point.
The PPS will rise again. There are NO shares to short so the NAKED SHORTS will HAVE TO cover the same day or pay for the shares. Would not want to be naked shorting this stock.
I agree with you there. I brought a decent lot on the ask just to see what would happen and the price dropped.
There are NO shares to short so the MM's just drag the PPS down, even on buys, to depress the rise. This will change next week when we get word of financing in place for the last trial.
Yep. Looking at level 2 they dancing around like mofos
There are ONLY 3 people in this company. They set the company up TO BE BOUGHT. We will hear something the week of the 5th after the conference. BIG MONEY investors are there just looking for good investments. This product has an 80% efficacy rating which is SUPER GOOD and why FDA fast tracked this cure.
Yea if the data is good big pharma will snatch them up. I still can’t believe they only have almost 2 million shares. This thing has the potential to explode
Not just one but TWO late stage phase 3 ready programs with FDA approval for fast track with a 1.6 m OS.
Their data is better then big pharma.
Totally correct: "I wouldn't be surprised they already have somebody lined up. 12 million market cap for a phase 2/3 breast cancer, FDA fast track designation, will propel this stock. "
This PPS will skyrocket when they get financing to perform phase 2/3 trials.
Under these circumstances after a huge reverse split, Biotechs come back with an offering, that has been the norm, strangely enough no filings, no self offering of some sort yet, that tells me, this company is aiming for a partnership at some point, the tale of the tape the story, they definitely don't want this sub $10.00, I will this is going to breakout fairly soon and I wouldn't be surprised they already have somebody lined up. 12 million market cap for a phase 2/3 breast cancer, FDA fast track designation, will propel this stock. Have a feeling this is the SAV*A.
MM's are controlling the PPS really tight, but, it will explode once they let it go. I see $20 to $30 dollars. Once this drug gets approved this PPS will be over $100.
Man if that’s true with such a small float omg this bad boy can explode
Market Makers are trying desperately to hold this PPS down.
NO shares available to short which means that there is a ton of NAKED SHORTING going on.
When the price of a stock is changing, impacting its prices by 10% or more within five minutes, it is a situation when a stock halt scenario gets triggered, and an exchange can put a halt to its trading.
Rather predictable huh? 10/30/22 Kintara Therapeutics's (NASDAQ:KTRA) short percent of float has risen 4894.88% since its last report. The company recently reported that it has 2.04 million shares sold short, which is 126.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 0.9 days to cover their short positions on average.
Yup it would not have lost 25% from $0.10 if it dropped to otc and another 50% in a few weeks at most like it probably will starting Monday.
I still say they should have let it go OTC, It's in a worse place now.
Well pre-split shares have essentially met my call of going to zero and it’s know untouchable post split while the short sellers masacre it down from $3.50-$4 when it opens Monday. The only thing to do now is buy it after any positive news that causes it to go higher and miss the first pop because it’s speculatively radioactive now to enter.
Yes it would be the best short term for current shareholders from a fiduciary aspect imo too but I figure ceo types egos and looking forward to obtaining financing, partner investors and eventually “product success” they will burn through replaceable stock to maintain the prestige listing. With no large block outside institutional ownership to influence decisions it’s at the mercy of the bod’s.
Once shareholders are this far underwater they vote for whatever lifeline is thrown their way.
I brought that up a couple months ago. I'd be fine with a drop to OTC. I'd buy my shares back in a hot minute.
Somebody on stocktwits posted this fwiw. Be interesting if they dropped to otc and avoided r/s and Nasdaq listing fees.
$KTRA hi, fellow investors I would like to share that I just finished a 30min zoom call with the CEO Mr.Hofman.
So, first of all, he is a great guy and seems to work in many directions for the company and the shareholders.
He believes that they are one of the only treatments left standing in the GCAR trails. He is reducing the cash burn rate to about 1M $ a month and has well enough for 1st Q 23 and will need about 9-10m$ to reach the finish line for GCAR results. there are risks and r/s may be in the cards, but also OTC is not a wrong place to rebuild since Inst are not in a habit to invest in 10 cents stocks.
I got a lot of confidence after talking to him (by the way, there is no 136m$ debt for the company as was misunderstood by another board. Its an accumulated loss). I will not sell my shares and will also add. Good luck to him and his staff and also to us.
There is a light at the end of this tunnel.
So far no! Only lower lows. Looks like it’s going to stay here until earnings and then get punished like a red head stepchild.
Are we sure this stock actually has a bottom other than $0.00?
Lol yes I think you’re right.
Kintara Therapeutics is focused on developing unique anti-cancer compounds, supported by a strong scientific rationale for development in indications with established biomarkers, and where patients are failing, or are unable to tolerate, current therapies.
VAL-083 is a "first-in-class" small molecule chemotherapeutic. Its unique structure provides many valuable benefits, including the targeting of DNA for its therapeutic effect and its ability to cross the blood brain barrier, critical for activity against central nervous system (CNS) tumors.
VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory glioblastoma multiforme (GBM) and is currently being studied in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM.
We are also pursuing the development of VAL-083 in the treatment of ovarian cancer.
REM-001 has broad utility for the treatment of serious cutaneous oncology indications. REM-001 has been previously studied in four Phase 2 and/or Phase 3 clinical trials in patients with cutaneous metastatic breast cancer (“CMBC”), who had previously received chemotherapy and/or failed radiation therapy.
Zacks Small-Cap Research
Based on our DCF model and a 15% discount rate, Kintara Therapeutics is valued at approximately $5.25 per share. Our model applies a 60% probability for VAL-083 in unmethylated GBM, a 50% probability in methylated GBM and a 50% probability of approval and commercialization in REM-001 for CMBC. The model includes contributions from the United States and Europe. Other regions will be included upon further clarity.
Shares Outstanding (mil) 43.2
Current Price (10/8/2021) $0.77
Thanks to its promising pipeline and $0.88 share price, 5-star analyst Michael King, of
H.C. Wainwright, sees an attractive entry point for investors.
“We are bullish about KTRA shares for the following five reasons
: (1) The GBM AGILE trial tests VAL-083 in
all three subtypes of GBM, allowing for multiple opportunities for VAL-083 to prove its
efficacy against phenotypically distinct types of the disease.
(2) VAL-083 is a bifunctional
alkylating agent that crosses the blood brain barrier and exhibits very favorable pharmacologic
properties relative TMZ; fulfilling the need for systemic availability in the brain.
has an established favorable safety record, both from initial trials and prior clinical use in
(4) Dire unmet need in GBM may present relatively low bar for approval.
(5) Phase 3 ready REM-001 is an additional bonus which is not factored into our valuation
assumptions and could potentially deliver value to shareholders while providing a backstop
against downside,” King explained.